News | July 27, 2021
Biocon Biologics partners Adagio to manufacture antibody for COVID-19
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The centralized marketing authorization granted by the EC is valid in all EU Member
The partnership is a significant step in delivering advanced cancer therapies to patients.
Biocon Ltd, an innovation-led global biopharmaceuticals company, has announced that the Board of its subsidiary Biocon Biologics Ltd has approved a primary equity investment of US $75 million (Rs. 555 crores) by Abu Dhabi based ADQ, one of the region’s largest holding companies.
Revenue from operations rose 14.8 per cent year-on-year to Rs. 3,942 crore
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
25 women students to receive internship, training, and mentorship in Life Sciences segment
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
Notably, 36 female students have been placed in Production and Manufacturing roles, reflecting the growing representation of women in core biotech operations
Subscribe To Our Newsletter & Stay Updated
